Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05239624
Title Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications

urethra transitional cell carcinoma

invasive bladder transitional cell carcinoma

ureter transitional cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

Therapies

Enfortumab vedotin-ejfv + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.